Key Highlights
- The Phase 3 CROSSING trial met both co-primary endpoints and all key secondary endpoints at week 24.
- Improvements were sustained through week 52 across both doses tested.
- Tezspire (tezepelumab) is already approved in other allergic and inflammatory indications.
- The data was disclosed on August 27, 2026.
A Positive Late-Stage Result in Eosinophilic Esophagitis
Amgen Inc. (NASDAQ:AMGN) said on August 27, 2026 that its Phase 3 CROSSING trial of Tezspire (tezepelumab) met its goals in eosinophilic esophagitis (EoE), a chronic immune-mediated condition in which a build-up of white blood cells called eosinophils inflames and damages the esophagus, often causing difficulty swallowing and food impaction. The trial demonstrated statistically significant and clinically meaningful improvements across both co-primary endpoints and all key secondary endpoints at week 24.
Durability Through One Year
Importantly, the improvements observed at week 24 were sustained through week 52 in both doses tested, indicating that the treatment effect held up over roughly a year of therapy rather than fading over time. Durability data of this kind is often a key consideration for chronic inflammatory conditions like EoE, where patients may require long-term management rather than a short course of treatment.
Context Within Amgen's Portfolio
Tezspire is already an approved therapy in other allergic and inflammatory indications, and a positive Phase 3 result in eosinophilic esophagitis would extend its potential use into an additional chronic condition, broadening the drug's addressable patient population within Amgen's (NASDAQ:AMGN) immunology franchise.
Market Reaction
Amgen (NASDAQ:AMGN) shares traded at $436.99, down 0.76%, with the company holding a market Capitalization of approximately $236.25 billion — reflecting Amgen's position as one of the largest companies in today's batch of updates.
What did the CROSSING trial evaluate?
The Phase 3 CROSSING trial evaluated Tezspire (tezepelumab), developed by Amgen (NASDAQ:AMGN), in eosinophilic esophagitis.
Did the trial meet its goals?
Yes, the trial met both co-primary endpoints and all key secondary endpoints at week 24, with improvements sustained through week 52.
What is eosinophilic esophagitis?
It is a chronic immune-mediated condition in which eosinophils build up in the esophagus, causing inflammation and symptoms such as difficulty swallowing.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...